Better healthcare starts with you
what is UKCTG?
Try searching for a clinical trial   You can search by condition or relevant keywords
in

Welcome to the UK Clinical Trials Gateway

Thank you for visiting the UK Clinical Trials Gateway. We hope it gives you a clear understanding of what is involved if you participate in a clinical trial. If you decide to sign up so that researchers can contact you about trials that might be suitable, you can do so here. You can also search this site in various ways to find trials relevant to you and contact researchers yourself.

But, before doing any of this, you may have questions about trials, what they are and how they work. Indeed, you may have come to this site because your doctor has invited you to join a trial but you want to know more before you decide.

Taking part in medical research is a big step. It can potentially deliver great benefits to you or a loved one but it may also involve some inconvenience or risk. This site includes plenty of information about what a trial involves and what you can expect if you take part (more here).

We hope the general information about trials is useful. You may find that individual trial records contain complex scientific and medical terms and are hard to understand. We are working to address this (more here) and hope that you are able to find out what you need from the contact named on the trial record or from your own doctor.

We continue to introduce and test new features on the site and welcome your feedback and comments.If you have any general questions about the UKCTG website or suggestions about how we can improve it, please feel free to contact us at ukctg@nihr.ac.uk.


Find trials near you.


Click on a location to see the trials running.


Latest research findings


from the NIHR Dissemination Centre

Research highlights the challenges of preventing diabetes with group education sessions
In people at high risk of type 2 diabetes, the educational programme ‘Let’s prevent’ had minimal impact on blood sugar control, and cholesterol. Overall it did not prevent people developing diabetes, though the risk was reduced for the 29% of people who attended all three sessions. The NIHR-funded trial compared three educational sessions plus telephone support with usual care. The main difficulty was recruitment and attendance. Only 19% of people at high risk of type 2 diabetes were willing to have a blood sugar test. Even when this showed high sugar levels, 23% of people allocated to the ‘Let’s prevent’ arm did not attend the first session. Other programmes – with more sessions over a longer period of time – have had a greater impact. The NHS is implementing a Diabetes Prevention Programme, involving 13 personalised education and exercise sessions over nine months. This trial highlights that focusing on maximising attendance will be vital to the success of this initiative.
14 March 2017

GP letter to improve medication adherence did not reduce unplanned care for children with asthma
A one-off GP letter reminding parents of children with asthma to use their medications over the August summer holiday did not prevent a characteristic annual peak in unplanned care on returning to school in September, but did lead to more prescriptions. Unplanned care represents visits to the GP or accident and emergency that is not part of the child’s asthma care plan. They do not include scheduled medical review or visits for repeat prescriptions. The letter prompted about a third more parents to collect inhaler prescriptions in August than parents receiving no letter. But this failed to reduce the high proportion of children receiving unplanned care in September (45% of children in the letter group compared to 44% in the control group). Most of the unplanned care was not for asthma, which may be why the letter had little impact. It remains unclear why children with asthma are more likely to access unplanned care. This NIHR-funded trial was large, well-designed and, despite problems with labelling planned and unplanned care, is likely to be reliable.
14 March 2017

Intensive follow-up following curative bowel cancer surgery may detect recurrent cancers sooner but does not improve survival
Intensive follow-up of patients who have been successfully treated for bowel cancer does not improve survival outcomes compared to less intensive follow-up. This systematic review included 15 randomised controlled trials comparing different intensities of follow-up. Protocols varied in terms of the number of tests, appointments or their setting (e.g. GP or hospital) - none of them affected survival. More intensive follow-up did however detect recurrent cancers sooner, and patients were twice as likely to undergo surgery again as a result. Evidence is limited for other outcomes, such as how different protocols impact cost or quality of life; on-going trials may shed light on this. Nevertheless, bowel cancer follow-up is time consuming and uses scarce NHS resources such as colonoscopy. If less intensive follow-up offers similar survival outcomes as more intensive approaches this may offer opportunities for savings.
28 February 2017

Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer
Postoperative radiotherapy increases the risk of death by 18% for patients with non-small cell lung cancer that has been removed by surgery. Just over half of patients (53%) given radiotherapy after surgery survived to two years following treatment. This compared to 58% of patients who did not receive postoperative radiotherapy. Previous evidence had suggested that postoperative radiotherapy may be beneficial after curative surgery. This Cochrane review contradicts this, drawing on data from 2,343 people across 11 good quality trials. It demonstrates that postoperative radiotherapy may have a detrimental effect on survival and cancer recurrence rates. Most of the trials are from over 30 years ago, so there is the possibility that newer radiotherapy techniques may be less harmful. Nevertheless, this review provides the best evidence to date that postoperative radiotherapy may not be appropriate as a routine treatment for non-small cell lung cancer.
28 February 2017

More research news on clinical trials

Better healthcare starts with you

The UK Clinical Trials Gateway is designed to help you participate in clinical trials running in the UK.

Read more